• Login
  • Register
Nairametrics
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
Nairametrics
Home Economy Socio Economic

AstraZeneca suspends COVID-19 vaccine final stage trial over safety concerns

Chike Olisah by Chike Olisah
September 9, 2020
in Socio Economic
AstraZeneca suspends COVID-19 vaccine final stage trial over safety concerns, COVID-19: J&J starts vaccine trials on humans after success on monkeys
Share on FacebookShare on TwitterShare on Linkedin

AstraZeneca Plc has suspended a final-stage trial of one of the leading Covid-19 vaccine candidates, after a suspected serious adverse reaction on one of the participants.

This was disclosed by a health news website, Stat News, on Tuesday, September 8, 2020, while quoting an AstraZeneca spokesperson.

The AstraZeneca official said, “Standard review process triggered a pause to vaccination to allow the review of safety data.”

MoreStories

Tinubunomics Not Working: SME’s groan over rising cost of doing business

September 21, 2025
IMF Spring Meetings: Edun, Cardoso declare Nigeria’s reforms are winning global endorsement

IMF Spring Meetings: Edun, Cardoso declare Nigeria’s reforms are winning global endorsement

April 26, 2025

AstraZeneca, in a statement, said that the trial was put on hold to conduct a standard review of the drugmaker’s vaccine trials after one person developed an unexplained illness. The pharmaceutical company said that this was intended to give researchers time to examine safety data while maintaining the integrity of the trials

READ: Moderna to supply 80 million doses of its COVID-19 vaccine to European Union

This study is testing a Covid-19 vaccine which is being developed by AstraZeneca in collaboration with University of Oxford researchers at various sites, including the United Kingdom, where this adverse reaction was reported.

The media report suggests that although the participant is expected to recover, details of the nature of the case and when it happened were not given.

Stat news said that the suspension of the trial has affected other vaccine trials by AstraZeneca as well as clinical trials being conducted by other vaccine makers, who are looking for signs of similar reactions.

READ: Moderna vaccine certified to protect monkeys against Coronavirus during study

The AstraZeneca spokesperson’s statement reads, “In large trials, illnesses will happen by chance but must be independently reviewed to check this carefully.”

Stat News reported that serious adverse reactions from the trials could have various outcomes such as issues that require hospitalization, life-threatening illness and death.

It can be recalled that 9 leading US and European vaccine developers, which include AstraZeneca, Pfizer Inc and GlaxoSmithKline, pledged on Tuesday to ensure scientific safety and efficacy standards for their vaccine candidates despite the alleged political pressure and urgency to contain the coronavirus pandemic.


Add Nairametrics on Google News
Follow us for Breaking News and Market Intelligence.
Tags: AstraZenecaCovid-19 vaccine
Chike Olisah

Chike Olisah

Chike was a banker with over 11 years experience in retail and commercial banking, risk management, treasury portfolio management and relationship management. He also acquired some experience in financial management and do have some special interest in investment analysis and personal finance. He had stints with financial institutions like the former Intercontinental Bank and Fidelity Bank.

Next Post
Tether expected to surpass Ethereum, based on strength of the U.S dollar, ther mints 80,000,000 USDT to unknown wallets within 24 hours, Tether mints over a billion dollars’ worth of USDT, Tether mints over a billion dollars’ worth of USDT

Tether mints 250,000,000 USDT

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Luis Figo
rabafast
nairametrics




DUNS

Follow us on social media:

  • ABOUT US
  • CONTACT US
  • PRODUCTS
  • ANDROID APP
  • iOS APP
  • DISCLAIMER
  • CAREERS
  • PRIVACY POLICY

© 2026 Nairametrics

Welcome Back!

Login to your account below

Forgotten Password? Sign Up

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
Social Media Auto Publish Powered By : XYZScripts.com
No Result
View All Result
  • Home
  • Exclusives
    • Recapitalization
      • Access Holdings Offer
      • Fidelity Bank Offer
      • GTCO Offer
      • Zenith Bank Offer
    • Financial Analysis
    • Corporate Stories
    • Interviews
    • Investigations
    • Metrics
    • Nairalytics
  • Economy
    • Business News
    • Budget
    • Public Debt
    • Tax
  • Markets
    • Currencies
    • Cryptos
    • Commodities
    • Equities
      • Company Results
      • Dividends
      • Public Offer & Right Issues
      • Stock Market News
    • Fixed Income
    • Funds Management
    • Securities
  • Sectors
    • Agriculture
    • Aviation
    • Company News
    • Consumer Goods
    • Corporate Updates
    • Corporate deals
    • Corporate Press Releases
    • Energy
    • Entertainment
    • Financial Services
    • Health
    • Hospitality & Travel
    • Manufacturing
    • Real Estate and Construction
    • Renewables & Sustainability
    • Tech News
  • Financial Literacy
    • Career tips
    • Personal Finance
  • Lifestyle
    • Billionaire Watch
    • Profiles
  • Opinions
    • Blurb
    • Market Views
    • Op-Eds
    • Research Analysis
  • Login
  • Sign Up

© 2026 Nairametrics